A phase 3 study in metastatic breast cancer reported that adding giredestrant to everolimus nearly doubles progression-free outcomes in patients, according to results from the evERA trial. The New England Journal of Medicine report described a significant extension of time without progression compared with the control arm, with benefits showing up across endpoints used to assess disease control. Giredestrant, an oral selective estrogen receptor degrader (SERD), was evaluated in combination with the mTOR inhibitor everolimus—an approach intended to address resistance mechanisms that emerge after earlier endocrine therapy. The study generated clinical evidence supporting the role of next-generation SERDs in combination strategies. The trial adds to growing momentum for oral endocrine-based regimens in advanced disease and increases pressure on competing therapies that rely on steroid receptor signaling interruption. Clinicians will likely focus next on patient selection markers and comparative sequencing versus other late-line endocrine combinations.